---
title: "Valion Bio | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286466910.md"
datetime: "2026-05-14T20:51:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286466910.md)
  - [en](https://longbridge.com/en/news/286466910.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286466910.md)
---

# Valion Bio | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -2.23.

EBIT: As of FY2026 Q1, the actual value is USD -5.634 M.

The provided reference, a Form 8-K filing by Valion Bio, Inc., indicates that the company issued a press release on May 14, 2026, regarding its financial results for the first quarter, ending March 31, 2026. This press release is furnished as Exhibit 99.1 to the Current Report. However, the reference text itself does not contain specific financial or operational metrics, such as revenue, net income, gross margin, operating profit, or cash flow. Additionally, no explicit outlook or guidance content is provided within the text of this Form 8-K filing.

### Related Stocks

- [VBIO.US](https://longbridge.com/en/quote/VBIO.US.md)

## Related News & Research

- [Gamehaus Holdings Inc. Announces Unaudited Financial Results for the Third Quarter of Fiscal 2026 Ended March 31, 2026 | GMHS Stock News](https://longbridge.com/en/news/289035965.md)
- [PowerFleet Q4 2026 Earnings Preview](https://longbridge.com/en/news/289616465.md)
- [Soybean Analysis: 2026 Market Volatility and Trend](https://longbridge.com/en/news/289444628.md)
- [Factorial Files Super 8-K Containing Q1 2026 Financial Results | FAC Stock News](https://longbridge.com/en/news/289602927.md)
- [Zedge Q3 2026 Earnings Preview](https://longbridge.com/en/news/289381005.md)